Nasdaq:US$14.72 (-0.05) | HKEX:HK$23.24 (+0.00) | AIM:£2.17 (-0.01)
Search Result
Previous Article   |   Next Article
Scientific Publications | 3 Nov 2021

NANETS 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors